IDEAYA Biosciences (NASDAQ: IDYA) insider transactions
In the twelve months to 10 November 2026, executives and directors of IDEAYA Biosciences reported 3 open-market sales of 35,888 shares ($1.4m) and 1 open-market purchase of 50,000 shares ($1.6m), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 October 2026 | Hata Yujiro S | President and CEO | Option exercise, 10b5-1 plan | +26,338 | $4.31 | 717,033 | Form 4 |
| 6 October 2026 | Hata Yujiro S | President and CEO | Open-market sale, 10b5-1 plan | −25,538 | $37.39 | 691,495 | Form 4 |
| 6 October 2026 | Hata Yujiro S | President and CEO | Open-market sale, 10b5-1 plan | −800 | $38.26 | 690,695 | Form 4 |
| 7 July 2026 | Ruiz Briseno Andres | Chief Accounting Officer | Option exercise | +9,550 | $12.86 | 36,016 | Form 4 |
| 7 July 2026 | Ruiz Briseno Andres | Chief Accounting Officer | Open-market sale | −9,550 | $40.01 | 26,466 | Form 4 |
| 2 March 2026 | Stein Jeffrey | Director | Open-market purchase | +50,000 | $32.96 | 54,281 | Form 4 |
| 28 November 2025 | Ruiz Briseno Andres | See Remarks | Grant or award | +1,253 | $16.91 | 26,466 | Form 4 |
| 28 November 2025 | Snyder Douglas B. | SVP, General Counsel | Grant or award | +1,041 | $16.91 | 2,080 | Form 4 |
| 30 May 2025 | Snyder Douglas B. | SVP, General Counsel | Grant or award | +1,039 | $16.91 | 1,039 | Form 4 |
| 18 February 2025 | Hata Yujiro S | President and CEO | Option exercise | +12,808 | $19.52 | 690,695 | Form 4 |
| 29 November 2024 | Ruiz Briseno Andres | See Remarks | Grant or award | +682 | $23.26 | 25,213 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the IDEAYA Biosciences page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.